Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Lophius Biosciences GmbH Joins NEU² and Receives Substantial Grant Funding


Lophius Biosciences GmbH Joins NEU˛ and Receives Substantial Grant Funding for the Diagnosis and Monitoring of Multiple Sclerosis

Hamburg/Regensburg, Germany, June 19, 2013 - Bionamics GmbH, the coordinator of the NEU˛ consortium,and Lophius Biosciences GmbH announced today that Lophius Biosciences has joined the NEU˛ program with a project addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression. This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.

Lophius Biosciences is a leading developer of innovative T cell based diagnostic test systems. One of the company’s platform technologies, the “Reverse T Cell Technology (RTT)”, represents a novel strategy for the diagnosis of T cell-mediated diseases. In contrast to available methods, RTT exploits the maturation processes induced in antigen presenting cells (APC) via a specific interaction with activated T helper (Th) cells thus representing an indirect measure for activated Th cells. Due to the high specificity of RTT for activated Th cells, the intended use of the RTT assay is the reliable detection of disease-specific activated Th cells as a novel biomarker for the diagnosis and monitoring of ongoing autoimmune diseases such as MS. The T-Track® MS test is aimed to fulfill unmet clinical needs offering a blood-based rapid and reliable differential diagnosis of MS complementary to the today’s state of the art clinical and MRT based diagnosis. Initial data from a collaboration between Lophius Biosciences and the Clinic and Policlinic for Neurology, University of Regensburg, and the Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, demonstrated preliminary clinical proof of principle for this MS test.

Dr. Michael Lutz and Prof. Dr. Ralf Wagner, Managing Directors of Lophius Biosciences commented: “We are very pleased to join the NEU˛ consortium. Both the opportunity to interact with leading experts in the MS field as well as the substantial funding will accelerate the development of our highly innovative T cell based diagnostic T-Track® MS test kit and help Lophius to initiate a broader clinical discovery and development program.”

Dr. Timm Jessen, CEO of Bionamics GmbH and founder of NEU˛, about the further expansion of the NEU˛ consortium: “With Lophius Biosciences we could attract an attractive new partner for the consortium. Its expertise in the diagnostic area will complement our expertises within NEU˛, also to the benefit of our current consortium members.”


About Lophius Biosciences GmbH
Lophius Biosciences GmbH, a German biotech company, is focusing on the development and marketing of innovative T-cell based diagnostic systems for the diagnosis and immunomonitoring in the fields of transplantation, infectious and autoimmune diseases. With its innovative products, the company also aims towards enabling therapy control and personalized treatment in the above fields of application.

About NEU˛
The NEU˛ consortium, including, amongst others, Merck KGaA, Evotec AG, European ScreeningPort GmbH, Bionamics GmbH, and the University Medical Center Hamburg-Eppendorf was successful in the nationwide “BioPharma” strategy competition of The Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung – BMBF). This initiative aims to promote innovative partnerships between academic institutions, biotechnology and pharmaceutical companies in order to strengthen the pharmaceutical value chain in Germany. The NEU˛ consortium focuses on the development of novel therapies against neurological diseases with a specific focus on multiple sclerosis. The NEU˛ consortium is coordinated by Bionamics GmbH, an independent project management company and founder of NEU˛.


Contact:
Lophius Biosciences GmbH
Prof. Dr. Ralf Wagner
Josef-Engert-Str. 13
D-93053 Regensburg
Phone: +49 941 6309 19785
Email: ralf.wagner@lophius.de
www.lophius.de


Publisher Contact Information:

Lophius Biosciences
+49 941 6309 19785
ralf.wagner@lophius.de

Company profile of Lophius Biosciences
Past press releases of Lophius Biosciences.

Data


27,242
Tech investments
From our Online Data Service
17,580
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jul 31€2.8MInternet services
Jul 30€9.5MWireless applications
Jul 30€4.5MSensors
Jul 30€5.0ME-Commerce
Jul 30N/ANetwork management
Jul 30€72.0MInternet services

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.